What is the recommended dose and timing of donepezil (cholinesterase inhibitor) for Alzheimer's disease treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Donepezil Dosing and Timing for Alzheimer's Disease

Start donepezil at 5 mg once daily in the evening just prior to retiring, then increase to 10 mg daily after 4-6 weeks if well tolerated. 1, 2, 3

Initial Dosing

  • The FDA-approved starting dose is 5 mg once daily, taken in the evening just before bedtime. 3
  • Donepezil can be taken with or without food, though taking it with food may reduce gastrointestinal side effects. 4, 1
  • The evening timing is important—administering donepezil at bedtime rather than morning increases the risk of sleep disturbances. 2

Dose Escalation for Mild to Moderate Alzheimer's Disease

  • Increase to 10 mg once daily after 4-6 weeks on the 5 mg dose. 1, 3
  • The 10 mg dose provides additional cognitive and functional benefits over 5 mg, with higher efficacy particularly for activities of daily living. 2, 5, 6
  • Do not rush the dose increase—the gradual 4-6 week titration period significantly improves tolerability and reduces gastrointestinal side effects compared to faster escalation schedules. 5, 7

Dose Escalation for Moderate to Severe Alzheimer's Disease

  • After at least 3 months on 10 mg daily, consider increasing to 23 mg once daily for moderate to severe disease. 3, 8
  • The 23 mg tablet must not be split, crushed, or chewed as it is a sustained-release formulation. 3
  • However, the 23 mg dose shows no greater efficacy than 10 mg but has higher rates of adverse events (particularly nausea at 11.8% vs 3.9%) and treatment withdrawals. 3, 6
  • Most patients will achieve adequate benefit on 10 mg daily without needing the 23 mg dose. 6

Expected Timeline for Assessment

  • An assessment period of 6-12 months is necessary to adequately evaluate treatment benefit. 1
  • Cognitive benefits can be observed as early as 3 weeks after starting treatment. 5
  • Benefits on cognition, activities of daily living, and behavior can be maintained for approximately 21-81 weeks with donepezil 10 mg daily. 2, 5

Side Effect Management

  • Monitor for dose-dependent gastrointestinal effects: nausea (relative risk 2.54), diarrhea (relative risk 2.57), and anorexia (relative risk 3.21). 2, 9
  • These effects are more common at 10 mg versus 5 mg, and dramatically more common at 23 mg versus 10 mg. 9, 3
  • Initial agitation may occur but typically subsides after the first few weeks. 4, 9
  • Unlike tacrine, donepezil does not cause hepatotoxicity and requires no liver function monitoring. 9

Common Pitfalls to Avoid

  • Do not prescribe donepezil for mild cognitive impairment—evidence shows no significant benefit in this population. 2
  • Do not escalate the dose too quickly—the 4-6 week interval between 5 mg and 10 mg is critical for tolerability. 3, 5
  • Do not administer in the morning—evening dosing reduces sleep disturbances. 2
  • Do not expect dramatic improvement—realistic expectations include slowing decline rather than reversing it, with effects that are statistically significant but modest in magnitude. 1, 2
  • Do not discontinue prematurely—some patients require up to 12 months to demonstrate benefit. 1
  • Be aware of potential interactions with cimetidine, theophylline, warfarin, and digoxin. 4, 9

References

Guideline

Alzheimer's Disease Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Initiation and Management of Donepezil and Memantine for Dementia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Donepezil for dementia due to Alzheimer's disease.

The Cochrane database of systematic reviews, 2018

Research

Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.

Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2009

Guideline

Common Side Effects of Donepezil

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.